U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06908642) titled 'Evaluation the Safety of hemay005 Tablets' on March 18.
Brief Summary: Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.
Study Start Date: Dec. 25, 2024
Study Type: INTERVENTIONAL
Condition:
Chronic Obstructive Pulmonary Disease
Intervention:
DRUG: Hemay005 tablet
Hemay005 is a small molecule PDE4 inhibitor.
DRUG: Placebo
Placebos are the same as drugs, but contain no Hemay005.
Recruitment Status: RECRUITING
Sponsor: Anhui Hemay Pharmaceutical Co., Ltd
Published by HT Digital Content Services with permission from Health Daily Dig...